Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Feature

Too many companies with biogeneric G-CSF products compete for a small market

Posted on: 17 Oct 05
Too many companies with biogeneric G-CSF products compete for a small market

Summary

More than 20 additional companies with activites in the biogeneric field of G-CSF were identified in a search conducted by La Merie Business Intelligence.

Amgen’s strategy to substitute its first generation granulocyte – colony stimulating factor (G-CSF) product Neupogen (filgrastim) by the longer acting, pegylated G-CSF product  Neulasta (pegfilgrastim) appears to be successful in protecting its US$ 2.9 bln combined global sales in 2004. The year 2004 conversion rate of 60 % for Neulasta (in its second year after approval) suggests that only a very small market will be left over for the five European companies with biosimilar versions of G-CSF when only the European patent expires in 2006. More than 20 additional companies with activites in the biogeneric field of G-CSF were identified in a search conducted by La Merie Business Intelligence. The results were published in the October 17 issue of R&D Pipeline News, edited by La Merie.


 


Biotechnology initiatives in India and China have lead to more than 20 domestic manufacturers of G-CSF and GM-CSF in China and at least seven Indian companies with proprietary manufacturing. As the domestic markets are too small (e.g. Indian market size of only US$ 25 mln due to low price products), Asian companies are collaborating with Western enterprises (GeneMedix, BioPartners and Dragon Pharmaceuticals) to pass the financial, regulatory and quality barriers and catch a piece of the Western market. South American manufacturers of G-CSF so far are exporting to developing countries only.


 


The real biogeneric challenge for established G-CSF marketers will come with patent expiry of pegylated G-CSF in 2013/15. So far, predominantly North American companies are working on next generation G-CSF products with longer half-life and increased efficacy. All of these projects still are in preclinical stages of R&D. G-CSF so far is indicated for prevention and treatment of neutropenia mainly due to chemotherapy.  Berlex (US-subsidiary of Schering AG) is in advanced clinical development of its GM-CSF product for treatment of Crohn’s disease which could more than double its sales once approved for this up side indication.


 


 



About La Merie


 


La Merie S.L. is a Business Intelligence enterprise fully dedicated to provide high quality R&D information to the biopharmaceutical industry. La Merie offers individual consultancy services and publishes reports and periodicals. For more information visit www.lamerie.com .


 


About R&D Pipeline News


 


R&D Pipeline News is a premier information source about research and development projects in the pipeline of the biopharmaceutical industry and is directed to all stakeholders in R&D. The weekly publication comes in a rapid- and easy-to-screen tabular format and provides access to the original information source via hyperlinks. R&D Pipeline News covers all relevant treatment modalities and is directly delivered to the desktop via e-mail.


More information about the journal, a free trial and subscriptions are available via the website, www.lamerie.com.

La Merie Business Intelligence PR

Last updated on: 27/08/2010 11:40:18

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.